Anti-PD-1 antibody (undisclosed)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-PD-1 antibody (undisclosed), covering 2026-02-27 to 2026-02-27. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors [NA]